Cargando…

Mucopolysaccharidosis III: Molecular basis and treatment

Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, I...

Descripción completa

Detalles Bibliográficos
Autores principales: Spahiu, Lidvana, Behluli, Emir, Peterlin, Borut, Nefic, Hilada, Hadziselimovic, Rifat, Liehr, Thomas, Temaj, Gazmend
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228206/
https://www.ncbi.nlm.nih.gov/pubmed/34743503
http://dx.doi.org/10.5114/pedm.2021.109270
_version_ 1785050918284165120
author Spahiu, Lidvana
Behluli, Emir
Peterlin, Borut
Nefic, Hilada
Hadziselimovic, Rifat
Liehr, Thomas
Temaj, Gazmend
author_facet Spahiu, Lidvana
Behluli, Emir
Peterlin, Borut
Nefic, Hilada
Hadziselimovic, Rifat
Liehr, Thomas
Temaj, Gazmend
author_sort Spahiu, Lidvana
collection PubMed
description Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options.
format Online
Article
Text
id pubmed-10228206
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-102282062023-06-05 Mucopolysaccharidosis III: Molecular basis and treatment Spahiu, Lidvana Behluli, Emir Peterlin, Borut Nefic, Hilada Hadziselimovic, Rifat Liehr, Thomas Temaj, Gazmend Pediatr Endocrinol Diabetes Metab Review paper | Praca poglądowa Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options. Termedia Publishing House 2021-09-30 2021-09 /pmc/articles/PMC10228206/ /pubmed/34743503 http://dx.doi.org/10.5114/pedm.2021.109270 Text en Copyright © Polish Society of Pediatric Endocrinology and Diabetes https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), allowing third parties to download and share its works but not commercially purposes or to create derivative works.
spellingShingle Review paper | Praca poglądowa
Spahiu, Lidvana
Behluli, Emir
Peterlin, Borut
Nefic, Hilada
Hadziselimovic, Rifat
Liehr, Thomas
Temaj, Gazmend
Mucopolysaccharidosis III: Molecular basis and treatment
title Mucopolysaccharidosis III: Molecular basis and treatment
title_full Mucopolysaccharidosis III: Molecular basis and treatment
title_fullStr Mucopolysaccharidosis III: Molecular basis and treatment
title_full_unstemmed Mucopolysaccharidosis III: Molecular basis and treatment
title_short Mucopolysaccharidosis III: Molecular basis and treatment
title_sort mucopolysaccharidosis iii: molecular basis and treatment
topic Review paper | Praca poglądowa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228206/
https://www.ncbi.nlm.nih.gov/pubmed/34743503
http://dx.doi.org/10.5114/pedm.2021.109270
work_keys_str_mv AT spahiulidvana mucopolysaccharidosisiiimolecularbasisandtreatment
AT behluliemir mucopolysaccharidosisiiimolecularbasisandtreatment
AT peterlinborut mucopolysaccharidosisiiimolecularbasisandtreatment
AT nefichilada mucopolysaccharidosisiiimolecularbasisandtreatment
AT hadziselimovicrifat mucopolysaccharidosisiiimolecularbasisandtreatment
AT liehrthomas mucopolysaccharidosisiiimolecularbasisandtreatment
AT temajgazmend mucopolysaccharidosisiiimolecularbasisandtreatment